Showing results (101-110 of 192) with videos related to
Sort By:
Pageof 20
European Journal of Cancer (Oxford, England : 1990)|November 21, 2021
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutationMichele Maio, Matteo S Carlino, Anthony M Joshua, et al.The Prostate|February 17, 2015
Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North AmericaAnthony M Joshua, Neal D Shore, Fred Saad, et al.Nature Nanotechnology|November 22, 2016
Tracking the dynamics of circulating tumour cell phenotypes using nanoparticle-mediated magnetic rankingMahla Poudineh, Peter M Aldridge, Sharif Ahmed, et al.Cancers|October 14, 2022
Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by SimvastatinBlossom Mak, Hui-Ming Lin, Thy Duong, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 10, 2022
<sup>177</sup>Lu-PSMA SPECT Quantitation at 6 Weeks (Dose 2) Predicts Short Progression-Free Survival for Patients Undergoing <sup>177</sup>Lu-PSMA-I&T TherapyNikeith John, Sarennya Pathmanandavel, Megan Crumbaker, et al.BJU International|May 24, 2021
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)Louise Emmett, Shalini Subramaniam, Anthony M Joshua, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 2024
Utility of <sup>64</sup>Cu-Sarcophagine-Bombesin PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal Findings on <sup>68</sup>Ga-PSMA-11 PET/CTSherrington Li, Andrew Nguyen, William Counter, et al.Therapeutic Advances in Medical Oncology|March 6, 2023
Patient outcomes following a response biomarker-guided approach to treatment using 177Lu-PSMA-I&T in men with metastatic castrate-resistant prostate cancer (Re-SPECT)Louise Emmett, Nikeith John, Sarennya Pathmanandavel, et al.European Urology Oncology|August 8, 2020
Phase I/II Trial of the Combination of <sup>177</sup>Lutetium Prostate specific Membrane Antigen 617 and Idronoxil (NOX66) in Men with End-stage Metastatic Castration-resistant Prostate Cancer (LuPIN)Megan Crumbaker, Sarennya Pathmanandavel, Andrew O Yam, et al.Plos One|November 19, 2010
Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)Linh T Nguyen, Pei Hua Yen, Jessica Nie, et al.Pageof 20